

Alessandro Russo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9022649/publications.pdf>

Version: 2024-02-01

111
papers

3,990
citations

134610

34
h-index

156644

58
g-index

112
all docs

112
docs citations

112
times ranked

5461
citing authors

#	ARTICLE	IF	CITATIONS
1	Multidrug-resistant <i>Acinetobacter baumannii</i> infections in COVID-19 patients hospitalized in intensive care unit. <i>Infection</i> , 2022, 50, 83-92.	2.3	81
2	Covid-19 sequelae in working age patients: A systematic review. <i>Journal of Medical Virology</i> , 2022, 94, 858-868.	2.5	26
3	The role of Gram-negative bacteria in skin and soft tissue infections. <i>Current Opinion in Infectious Diseases</i> , 2022, 35, 95-102.	1.3	7
4	The Interplay between Host Defense, Infection, and Clinical Status in Septic Patients: A Narrative Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 803.	1.8	8
5	Role of the T2Dx magnetic resonance assay in patients with suspected bloodstream infection: a single-centre real-world experience. <i>BMC Infectious Diseases</i> , 2022, 22, 113.	1.3	6
6	Antibiotic treatment of acute bacterial skin and skin structure infections. <i>Current Opinion in Infectious Diseases</i> , 2022, 35, 120-127.	1.3	5
7	Bacterial Ventilator-Associated Pneumonia in COVID-19 Patients: Data from the Second and Third Waves of the Pandemic. <i>Journal of Clinical Medicine</i> , 2022, 11, 2279.	1.0	13
8	Similarities, differences, and possible interactions between hepatitis E and hepatitis C viruses: Relevance for research and clinical practice. <i>World Journal of Gastroenterology</i> , 2022, 28, 1226-1238.	1.4	3
9	Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Infections in Patients With Liver Cirrhosis. <i>Journal of Clinical and Experimental Hepatology</i> , 2022, 12, 1293-1300.	0.4	3
10	Is the Pendulum of Antimicrobial Drug Resistance Swinging Back after COVID-19?. <i>Microorganisms</i> , 2022, 10, 957.	1.6	12
11	Cytokine Profile of Invasive Pulmonary Aspergillosis in Severe COVID-19 and Possible Therapeutic Targets. <i>Diagnostics</i> , 2022, 12, 1364.	1.3	5
12	Clinical Characteristics and Outcome of Hospitalized COVID-19 Patients Treated with Standard Dose of Dexamethasone or High Dose of Methylprednisolone. <i>Biomedicines</i> , 2022, 10, 1548.	1.4	2
13	Daptomycin Population Pharmacokinetics in Patients Affected by Severe Gram-Positive Infections: An Update. <i>Antibiotics</i> , 2022, 11, 914.	1.5	5
14	Efficacy of a Fosfomycin-Containing Regimen for Treatment of Severe Pneumonia Caused by Multidrug-Resistant <i>Acinetobacter baumannii</i> : A Prospective, Observational Study. <i>Infectious Diseases and Therapy</i> , 2021, 10, 187-200.	1.8	41
15	Broadly reactive human CD4 ⁺ T cells against Enterobacteriaceae are found in the naïve repertoire and are clonally expanded in the memory repertoire. <i>European Journal of Immunology</i> , 2021, 51, 648-661.	1.6	13
16	Predictors of intensive care unit admission in patients with <i>Legionella pneumoniae</i> : role of the time to appropriate antibiotic therapy. <i>Infection</i> , 2021, 49, 321-325.	2.3	18
17	Targeting Microbiome: An Alternative Strategy for Fighting SARS-CoV-2 Infection. <i>Chemotherapy</i> , 2021, 66, 24-32.	0.8	22
18	First report of spondylodiscitis caused by <i>Bacillus circulans</i> in an immunocompetent patient: Clinical case and review of the literature. <i>IDCases</i> , 2021, 23, e01058.	0.4	4

#	ARTICLE	IF	CITATIONS
19	Post-Traumatic Stress Symptoms in Healthcare Workers Dealing with the COVID-19 Pandemic: A Systematic Review. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 601.	1.2	187
20	Procalcitonin in daily clinical practice: an evergreen tool also during a pandemic. <i>Internal and Emergency Medicine</i> , 2021, 16, 541-543.	1.0	7
21	Ceftazidime-Avibactam Use for <i>Klebsiella pneumoniae</i> Carbapenemase-Producing <i>K. pneumoniae</i> Infections: A Retrospective Observational Multicenter Study. <i>Clinical Infectious Diseases</i> , 2021, 73, 1664-1676.	2.9	130
22	Recent molecules in the treatment of severe infections caused by ESBL-producing bacteria. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 983-991.	2.0	11
23	Effect of N-Acetylcysteine Administration on 30-Day Mortality in Critically Ill Patients with Septic Shock Caused by Carbapenem-Resistant <i>Klebsiella pneumoniae</i> and <i>Acinetobacter baumannii</i> : A Retrospective Case-Control Study. <i>Antibiotics</i> , 2021, 10, 271.	1.5	13
24	The role of teicoplanin in the treatment of SARS-CoV-2 infection: A retrospective study in critically ill COVID-19 patients (Tei-COVID study). <i>Journal of Medical Virology</i> , 2021, 93, 4319-4325.	2.5	20
25	Viral community acquired pneumonia at the emergency department: Report from the pre COVID-19 age. <i>Journal of Medical Virology</i> , 2021, 93, 4399-4404.	2.5	7
26	Early antibiotic treatment in emergency department: the critical balance. <i>Internal and Emergency Medicine</i> , 2021, 16, 1743-1745.	1.0	0
27	Clinical Characteristics and Outcome of Patients with Suspected COVID-19 in Emergency Department (RESILIENCY Study II). <i>Diagnostics</i> , 2021, 11, 1368.	1.3	3
28	Editorial: Spotlight on the Relationship Between Sepsis and Infection: From Mechanisms to Therapy. <i>Frontiers in Medicine</i> , 2021, 8, 716215.	1.2	1
29	Efficacy of Remdesivir-Containing Therapy in Hospitalized COVID-19 Patients: A Prospective Clinical Experience. <i>Journal of Clinical Medicine</i> , 2021, 10, 3784.	1.0	12
30	Vertebral osteomyelitis caused by vancomycin-resistant <i>Enterococcus</i> spp.: a case series. <i>International Journal of Antimicrobial Agents</i> , 2021, 58, 106432.	1.1	2
31	SARS-CoV-2 Among Migrants Recently Arrived in Europe From Low- and Middle-Income Countries: Containment Strategies and Special Features of Management in Reception Centers. <i>Frontiers in Public Health</i> , 2021, 9, 735601.	1.3	2
32	Lesson learned from the 2017 measles outbreak in Italy: report from an emergency department. <i>Infezioni in Medicina</i> , 2021, 29, 252-258.	0.7	1
33	Role of procalcitonin in predicting etiology in bacteremic patients: Report from a large single-center experience. <i>Journal of Infection and Public Health</i> , 2020, 13, 40-45.	1.9	21
34	Inhaled Liposomal Antimicrobial Delivery in Lung Infections. <i>Drugs</i> , 2020, 80, 1309-1318.	4.9	75
35	Comparison Between Hospitalized Patients Affected or Not Affected by Coronavirus Disease 2019. <i>Clinical Infectious Diseases</i> , 2020, 72, e1158-e1159.	2.9	7
36	Role of Low-Molecular-Weight Heparin in Hospitalized Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia: A Prospective Observational Study. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa563.	0.4	48

#	ARTICLE	IF	CITATIONS
37	Procalcitonin in the Assessment of Ventilator Associated Pneumonia: A Systematic Review. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1323, 103-114.	0.8	14
38	Efficacy of Daptomycin-Containing Regimen for Treatment of Staphylococcal or Enterococcal Vertebral Osteomyelitis: A Prospective Clinical Experience. <i>Antibiotics</i> , 2020, 9, 889.	1.5	3
39	COVID-19 and kidney transplantation: an Italian Survey and Consensus. <i>Journal of Nephrology</i> , 2020, 33, 667-680.	0.9	40
40	Gram-negative septic thrombosis in critically ill patients: A retrospective case-control study. <i>International Journal of Infectious Diseases</i> , 2020, 94, 110-115.	1.5	5
41	Pulmonary Aspergillosis: An Evolving Challenge for Diagnosis and Treatment. <i>Infectious Diseases and Therapy</i> , 2020, 9, 511-524.	1.8	45
42	Ceftaroline for severe community-acquired pneumonia: A real-world two-centre experience in Italy and Spain. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105921.	1.1	9
43	Clinical features, therapy and outcome of patients hospitalized or not for nursing-home acquired pneumonia. <i>Journal of Infection and Chemotherapy</i> , 2020, 26, 807-812.	0.8	9
44	Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing Enterobacterales Infections: A Multicenter Nationwide Clinical Experience (CEFTABUSE II Study). <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa139.	0.4	49
45	Spotlight on New Antibiotics for the Treatment of Pneumonia. <i>Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine</i> , 2020, 14, 117954842098278.	0.5	10
46	Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPC-producing <i>Klebsiella pneumoniae</i> . <i>Critical Care</i> , 2020, 24, 29.	2.5	121
47	Clinical features and outcome of difficult-to-treat infections in a high-intensity medical care ward. <i>Minerva Medica</i> , 2020, , .	0.3	5
48	Daptomycin-containing regimens for treatment of Gram-positive endocarditis. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 423-434.	1.1	10
49	Management of vertebral osteomyelitis over an eight-year period: The UDIPROVE (UDIne PROtocol on) Tj ETQq1 1 0.784314 rrgBT /Ov	1.5	26
50	Emerging drugs for treating methicillin-resistant <i>Staphylococcus aureus</i> . <i>Expert Opinion on Emerging Drugs</i> , 2019, 24, 191-204.	1.0	9
51	Should High-dose Daptomycin be an Alternative Treatment Regimen for Enterococcal Endocarditis?. <i>Infectious Diseases and Therapy</i> , 2019, 8, 695-702.	1.8	10
52	Bloodstream infections caused by carbapenem-resistant <i>Acinetobacter baumannii</i> : Clinical features, therapy and outcome from a multicenter study. <i>Journal of Infection</i> , 2019, 79, 130-138.	1.7	67
53	Role of procalcitonin in bacteremic patients and its potential use in predicting infection etiology. <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 99-105.	2.0	30
54	Ceftolozane/tazobactam for the treatment of serious <i>Pseudomonas aeruginosa</i> infections: a multicentre nationwide clinical experience. <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 408-415.	1.1	120

#	ARTICLE	IF	CITATIONS
55	A Hypothesis-Generating Study of the Combination of Aspirin plus Macrolides in Patients with Severe Community-Acquired Pneumonia. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	15
56	Comparison of Septic Shock Due to Multidrug-Resistant <i>Acinetobacter baumannii</i> or <i>Klebsiella pneumoniae</i> Carbapenemase-Producing <i>K. pneumoniae</i> in Intensive Care Unit Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	47
57	Predictors of mortality in nursing-home residents with pneumonia: a multicentre study. <i>Clinical Microbiology and Infection</i> , 2018, 24, 72-77.	2.8	28
58	New Antibiotics for Pneumonia. <i>Clinics in Chest Medicine</i> , 2018, 39, 853-869.	0.8	18
59	Comparison between procalcitonin and C-reactive protein to predict blood culture results in ICU patients. <i>Critical Care</i> , 2018, 22, 252.	2.5	16
60	Rational approach in the management of <i>Pseudomonas aeruginosa</i> infections. <i>Current Opinion in Infectious Diseases</i> , 2018, 31, 578-586.	1.3	37
61	Risk stratification and treatment of ICU-acquired pneumonia caused by multidrug-resistant/extensively drug-resistant/pandrug-resistant bacteria. <i>Current Opinion in Critical Care</i> , 2018, 24, 385-393.	1.6	95
62	Multidrug-resistant <i>Klebsiella pneumoniae</i> : challenges for treatment, prevention and infection control. <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 749-761.	2.0	123
63	Management of patients with septic shock due to <i>Candida</i> infection. <i>Hospital Practice (1995)</i> , 2018, 46, 258-265.	0.5	5
64	Antimicrobial resistance and treatment: an unmet clinical safety need. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 669-680.	1.0	27
65	Prospective evaluation of the aetiology of acute otitis media with spontaneous tympanic membrane perforation. <i>Clinical Microbiology and Infection</i> , 2017, 23, 486.e1-486.e6.	2.8	27
66	Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 726-734.	4.6	367
67	Assessment of risk factors for candidemia in non-neutropenic patients hospitalized in Internal Medicine wards: A multicenter study. <i>European Journal of Internal Medicine</i> , 2017, 41, 33-38.	1.0	35
68	<i>Candida</i> endocarditis: systematic literature review from 1997 to 2014 and analysis of 29 cases from the Italian Study of Endocarditis. <i>Expert Review of Anti-Infective Therapy</i> , 2017, 15, 807-818.	2.0	23
69	Role of oral nystatin prophylaxis in cardiac surgery with prolonged extracorporeal circulation. <i>Mycoses</i> , 2017, 60, 826-829.	1.8	5
70	Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study. <i>International Journal of Antimicrobial Agents</i> , 2017, 50, 664-672.	1.1	8
71	Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β -Lactamase-Producing Enterobacteriaceae: Results From the INCREMENT Cohort. <i>Clinical Infectious Diseases</i> , 2017, 65, 1615-1623.	2.9	43
72	A Multinational, Preregistered Cohort Study of β -Lactam/ β -Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum β -Lactamase-Producing Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4159-4169.	1.4	137

#	ARTICLE	IF	CITATIONS
73	Current and future trends in antibiotic therapy of acute bacterial skin and skin-structure infections. <i>Clinical Microbiology and Infection</i> , 2016, 22, S27-S36.	2.8	122
74	A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae. <i>Mayo Clinic Proceedings</i> , 2016, 91, 1362-1371.	1.4	89
75	Candidemia in Patients with Body Temperature Below 37°C and Admitted to Internal Medicine Wards: Assessment of Risk Factors. <i>American Journal of Medicine</i> , 2016, 129, 1330.e1-1330.e6.	0.6	16
76	Impaired flow-mediated dilation in hospitalized patients with community-acquired pneumonia. <i>European Journal of Internal Medicine</i> , 2016, 36, 74-80.	1.0	15
77	Low-grade endotoxemia, gut permeability and platelet activation in community-acquired pneumonia. <i>Journal of Infection</i> , 2016, 73, 107-114.	1.7	45
78	Hospitalization for Pneumonia is Associated With Decreased 1-Year Survival in Patients With Type 2 Diabetes. <i>Medicine (United States)</i> , 2016, 95, e2531.	0.4	25
79	Candidaemia after heart valve replacement surgery: recurrence as prosthetic valve endocarditis is an expected over one-year complication. <i>Clinical Microbiology and Infection</i> , 2016, 22, 466-467.	2.8	7
80	Predictors of outcome in ICU patients with septic shock caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. <i>Clinical Microbiology and Infection</i> , 2016, 22, 444-450.	2.8	112
81	Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1672-1680.	1.3	41
82	Septic shock from community-onset pneumonia: is there a role for aspirin plus macrolides combination?. <i>Intensive Care Medicine</i> , 2016, 42, 301-302.	3.9	16
83	Risk Factors and Outcomes for Bloodstream Infections Secondary to Clostridium difficile Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 252-257.	1.4	45
84	Spontaneous bacterial peritonitis due to methicillin-resistant Staphylococcus aureus in a patient with cirrhosis: the potential role for daptomycin and review of the literature. <i>Gastroenterology Insights</i> , 2015, 7, 6127.	0.7	6
85	Reply to: "The Possible Role of Anti-Methicillin-Resistant Staphylococcus Aureus Antimicrobial Agents in Spontaneous Bacterial Peritonitis". <i>Gastroenterology Insights</i> , 2015, 7, 6356.	0.7	0
86	Relation of Cardiac Complications in the Early Phase of Community-Acquired Pneumonia to Long-Term Mortality and Cardiovascular Events. <i>American Journal of Cardiology</i> , 2015, 116, 647-651.	0.7	110
87	Nox2 up-regulation is associated with an enhanced risk of atrial fibrillation in patients with pneumonia. <i>Thorax</i> , 2015, 70, 961-966.	2.7	38
88	Linezolid-resistant staphylococcal bacteraemia: A multicentre case-control study in Italy. <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 255-261.	1.1	30
89	Lower Mortality Rate in Elderly Patients With Community-Onset Pneumonia on Treatment With Aspirin. <i>Journal of the American Heart Association</i> , 2015, 4, e001595.	1.6	78
90	Risk factors and clinical outcomes of candidaemia in patients treated for Clostridium difficile infection. <i>Clinical Microbiology and Infection</i> , 2015, 21, 493.e1-493.e4.	2.8	29

#	ARTICLE	IF	CITATIONS
91	Optimizing antibiotic therapy of bacteremia and endocarditis due to staphylococci and enterococci: New insights and evidence from the literature. <i>Journal of Infection and Chemotherapy</i> , 2015, 21, 330-339.	0.8	33
92	Individualizing Risk of Multidrug-Resistant Pathogens in Community-Onset Pneumonia. <i>PLoS ONE</i> , 2015, 10, e0119528.	1.1	55
93	Reply to Di Paolo et al. <i>Clinical Infectious Diseases</i> , 2014, 58, 1789-1790.	2.9	6
94	CAP and HCAP are different? An unresolved question. <i>Thorax</i> , 2014, 69, 676-677.	2.7	2
95	Early, intermediate and late infectious complications after transcatheter or surgical aortic-valve replacement: a prospective cohort study. <i>Clinical Microbiology and Infection</i> , 2014, 20, 758-763.	2.8	18
96	Healthcare-associated pneumonia: a never-ending story. <i>Gastroenterology Insights</i> , 2014, 6, 5387.	0.7	2
97	Simplified Equations Using Two Concentrations To Calculate Area under the Curve for Antimicrobials with Concentration-Dependent Pharmacodynamics: Daptomycin as a Motivating Example. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3162-3167.	1.4	36
98	Early identification of severe community-onset pneumonia in "frail elderly patient". <i>Internal and Emergency Medicine</i> , 2014, 9, 119-120.	1.0	6
99	Healthcare-Associated Pneumonia and Multidrug-Resistant Bacteria: Do We Have a Convincing Answer?. <i>Clinical Infectious Diseases</i> , 2014, 58, 1196-1197.	2.9	5
100	Platelet Activation Is Associated With Myocardial Infarction in Patients With Pneumonia. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1917-1925.	1.2	134
101	Is NOX2 Upregulation Implicated in Myocardial Injury in Patients with Pneumonia?. <i>Antioxidants and Redox Signaling</i> , 2014, 20, 2949-2954.	2.5	25
102	Predictors of mortality in non-neutropenic patients with invasive pulmonary aspergillosis: does galactomannan have a role?. <i>Diagnostic Microbiology and Infectious Disease</i> , 2014, 80, 83-86.	0.8	20
103	Variability of pharmacokinetic parameters in patients receiving different dosages of daptomycin: is therapeutic drug monitoring necessary?. <i>Journal of Infection and Chemotherapy</i> , 2013, 19, 732-739.	0.8	65
104	Correlation between glycemic trends assessed by 24h continuous monitoring and autonomic activity in patients with recent onset type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2013, 100, e14-e16.	1.1	2
105	Considerations for Higher Doses of Daptomycin in Critically Ill Patients With Methicillin-Resistant <i>Staphylococcus aureus</i> Bacteremia. <i>Clinical Infectious Diseases</i> , 2013, 57, 1568-1576.	2.9	118
106	Candidemia Subsequent to Severe Infection Due to <i>Clostridium difficile</i> : Is There a Link?. <i>Clinical Infectious Diseases</i> , 2013, 57, 772-774.	2.9	29
107	Daptomycin serum levels in critical patients undergoing continuous renal replacement. <i>Journal of Chemotherapy</i> , 2012, 24, 253-256.	0.7	21
108	Retrospective case-control analysis of patients with staphylococcal infections receiving daptomycin or glycopeptide therapy. <i>International Journal of Antimicrobial Agents</i> , 2012, 39, 64-68.	1.1	36

#	ARTICLE	IF	CITATIONS
109	Invasive aspergillosis in patients with liver disease. <i>Medical Mycology</i> , 2011, 49, 406-413.	0.3	78
110	Invasive Pulmonary Aspergillosis in Non-Neutropenic Patients: Analysis of a 14-Month Prospective Clinical Experience. <i>Journal of Chemotherapy</i> , 2011, 23, 290-294.	0.7	18
111	Clinical Experience of Anidulafungin for the Treatment of Patients with Documented Candidemia. <i>Journal of Chemotherapy</i> , 2010, 22, 397-401.	0.7	3